Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEISH-F2 + MPL-SE
- Development stage
- Phase 2
- Lead developer
- Access to Advanced Health Institute
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LEISH-F2 + MPL-SE is a second-generation recombinant protein vaccine developed for the treatment and prevention of leishmaniasis, particularly cutaneous leishmaniasis (CL) and post-kala-azar dermal leishmaniasis (PKDL). The vaccine consists of the LEISH-F2 antigen—a recombinant fusion protein derived from three conserved Leishmania antigens (thiol-specific antioxidant [TSA], stress-inducible protein 1 [LmSTI1], and elongation initiation factor [LeIF])—combined with the adjuvant monophosphoryl lipid A in a stable oil-in-water emulsion (MPL-SE). The mechanism of action involves immunostimulation, specifically activating T cell responses to induce protective immunity against Leishmania parasites. Clinical trials have demonstrated that this formulation is safe, well-tolerated, and capable of inducing strong cellular immune responses in humans. It has reached Phase 2 clinical development for cutaneous leishmaniasis[1][4][6].
- Brand names
- LEISH-F2 + MPL-SE
- Other names
- LEISH-F2/MPL-SE vaccineLeishmania F2 recombinant protein plus monophosphoryl lipid A-stable emulsion
02
Targets
TLR4 (Toll-like receptor 4)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on LEISH-F2 + MPL-SE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEISH-F2 + MPL-SE.